louisa,


"And the stock is not selling off because people on the message boards that you read are losing confidence in the company. Small cap and biotech investors have been obliterated this year, and this quarter in particular. Funds are blowing out of their holdings to show investors that they have no exposure to the sector at the end of the quarter"

so what does the bolded part have to do with us?..:)

Advanced Cell Technology, Inc. (ACTC) Detailed Institutional Holdings
574,300

the real question that has the Street puzzled is "who will pay for the trials in the near term

•The Company ended 2011 Q2 with $16.1 million cash on hand
•$17 million more equity available
•Virtually debt-free
•Able to self-fund both U.S. clinical trials and EP clinical trial

slide 28 from 2 weeks ago
http://www.advancedcell.com/documents/0000/0348/act-corporate-presentation--stem-cell-congress-boston-september-2011.pdf

no idea what ALL the potential liabilities are. Here is a post of my opinion of what is needed to cover the last 8K should ACT lose them all but it doesn't cover Aronson or Gortons lawsuit..Keep in mind too we operate with shares on all fronts so it will take shares and plenty of them until we either have substantial revenues or JV with a sugar daddy..until then it is all shares.
http://investorstemcell.com/forum/act-sec-documents-legal-matters-patents/7412.htm#post33338

louisa,

nothing to do with scheduled Lanza shares. Could be one of many debt holders who have received discounted shares in settlements, lawsuits etc..

Pursuant to Dr. Lanza’s 10b-5 trading plan, a brokerage firm may sell up to 18,500,000 shares of the Company's common stock owned by him, at price intervals ranging between $0.25 and $1.00.
http://www.sec.gov/Archives/edgar/data/1140098/000114420411034356/v225200_8k.htm

north,

open the link under the first post I sent you, it's from an I-hub message post in 2009..I sent that old message because you mentioned Cordis in your post..that's all it was, no more..
you needn't e-mail anyone about the agreement, it is long ago dead.

north,


I was unable to confirm a PR with today's date from either company

what makes you think there is a PR on this today? That trial has been a dead horse since Feb of 2008.
http://clinicaltrials.gov/ct2/show/NCT00626314?term=mytogen&rank=1

http://www.advancedcell.com/news-and-media/press-releases/advanced-cell-technology-announces-catheter-supply-agreement-with-biologics-delivery-systems-group/index.asp

north,


Advanced Cell Technology, Inc. (OTCBB: ACTC) announced today that it has reached a supply agreement with Biologics Delivery Systems Group, Cordis Corporation (a Johnson & Johnson company), in which Biologics Delivery Systems will supply catheters for the Phase II human clinical trial of ACT’s myoblast therapy for the treatment of heart failure
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=34729427

alaeloa,


IMO, no, a share buy back will not happen. ACT has 2 trials in progress, one approved to for the UK yesterday, and upcoming IND filings in other areas. ACT will need cash and lots of it especially when entering the larger Phase 2 studies, especially for dryAMD.

Many things are in play now with Corporate. We are very close to maxing out the AS# of 1.75B. They will need to ask shareholders to vote for an increase. In Rodman conference presentation Rabin stated a national exchange is "front of mind". Rabin has stated prior the only thing holding ACT back from an uplist is the price per share. There are 2 ways to get the price per share up to approx. $4/shares needed to uplist.

1)ACT does it on their own with news
2)reverse split

alaeloa,

The question is more than appropriate. Answer, we do not have the money to buy back shares. The CASH we have is for operations and trials.

hi louisa,


If a JV were to take place and monies were fronted to ACT it would
be helpful for any future financing in the sense we would not have to use shares.
I, like you, believe it will be a while before that happens. If you or others haven't read the e-mail
from Matt Vincent,Director, Business Development, it contains info that mirrors thoughts
I had on the topic. Here it is thanks to poster twenty2...Bolding is mine.


Many thanks for your note. It was great to meet you at the shareholder meeting this past June. I hope you have had a wonderful summer since then.

As we have not said much publicly about the phase II trial design, there is only so much I can say about it in this email. It will be longer than the Phase I study (which will run about 1 year), but not substantially longer. I anticipate that Phase II will take from 18 – 30 months. Sorry to give you such a wide range, but until we have provided more details publicly I need to keep my comments within the context of what we have already presented. That being said, I took a look at the thread around video and think I understand the context of your question – can we afford to go through Phase II without a partner. We do have a reasonably good understanding of the costs associated with the Phase II arms to each trial, and between our cash on hand and the equity line we have in place, we could advance both IND’s through Phase II without sacrificing the other programs we continue to make excellent progress advancing toward the clinic as well.

It was enlightening to see the various efforts to “read the tea leaves” from my discussion on the BioPharm panel last week. And I cannot tell you how much appreciated the positive things that folks said about me – it means a great deal to each of us at ACT to know the support we have from our shareholders. So thank-you, you are wonderful. I would add this around the partnering discussion though on the thread, at least to clarify. As I mentioned, the typical big Pharma disposition these days around clinical and preclinical opportunities is a desire to see phase II data before real partnering considerations are made. There are plenty of exceptions to trend for sure, and our SMD and dry AMD trials are designed such we have some unique opportunities even within the current trends. Indeed, it is clear from the meetings we have been attending that ACT is being closely followed by many of the big Pharma and biotech companies. I think more than one person picked that up in Garry Neil’s (J+J) comments.

While our phase I study is designed for safety, we have a unique opportunity through imaging of the retinas of our patients to follow RPE cell engraftment and photoreceptor activity, and along with a variety of other tests our patients are undergoing we hope to be able to produce relevant physiological data that would be of interest to potential strategic partners even before the commencement of Phase II. The calculation for us, if a potential partnership were put on the table to consider before we began Phase II, will be whether the economics of the deal (and what that money would mean to advancing other programs) and the manpower and experience that the partner could bring to bear make sense when compared to the potential increase in value of the program that a positive Phase II trial might have (factoring in the risks of the trial as well) if we were to fund the trial ourselves and wait. The bottom line is that I believe we are in the very fortunate position of having many many more choices when compared to most other companies out there with products moving through the clinic. As Gary would say, all options are on the table for consideration. It is a very exciting time.

All the best
Matt
Matthew Vincent, Ph.D.
Director, Business Development
Advanced Cell Technology, Inc.
33 Locke Drive
Marlborough, MA 01752
http://investorstemcell.com/forum/act-main-forum-general-topics-science-press-releases-media/7110.htm

fwiw,

Lawsuit, fairness hearings and settlements: Last 30 months..541MM shares
http://investorstemcell.com/forum/act-sec-documents-legal-matters-patents/7412-3.htm#post33446

hopefulstem,

actc has taken a hit from these things, mainy in lawyer fee's and being tied up in court

you forgot many shares issued. The 8K filed by ACT yesterday is telling you the possibility exist the current lawsuit(and others who may follow), would dwarf anything to date. This does not include the Aronson?Gorton cases either. Mega shares equals more dilution of which we have had plenty..

penny,

not that I am aware of, and you?

louisa,

silk sheets..lmao I truly believe what I posted there, if Rabin accomplishes what I posted things would be that "smooth"..:)
That's when we can exhale...

louisa,

thanks, I am aware they have no problem suing, that alone doesn't mean their case has no merit. They were a CD holder here for many years, filed and won a suit in 2009(see below). Part of the settlement gave them another debenture, unreal. Anyway, todays 8K is addressing all convertibles as they are tied together. Hopefully this time things go
differently..I am guessing in 30 days we know something because Alpha has filed for preliminary and permanent injunction against ACT..thanks again


On June 30, 2009, Alpha Capital submitted a conversion notice in the principle amount of $150,000 into 7,500,000 shares of common stock at $0.02 per share. The Company did not have sufficient authorized shares to satisfy this conversion notice. On July 6, 2009, by means of a settlement between the 2 parties, the Company agreed to deliver the 7,500,000 shares of its common stock no later than September 25, 2009. Further, the Company agreed to provide Alpha Capital with an additional $110,000 Debenture, which is to be upon the same terms and conditions as the April 2008 Debenture.

A post I made on I-cell on the 8K,

hi saxxie,

todays 8K and how I understand it to read. It should first be noted "other holders of convertible
notes and warrants issued by the Company". This implies 2 things. it means it is in addition to
the already filed Alpha suit(other holders) and it applies only to convertibles so the Aronson
case nor the Gorton case are included. Therefore:

39,514,859 shares of its common stock plus 8 Million common
plus 380MM warrants(converts to common) equals a total of 427,514,859 shares
Aronson/Gorton NOT included

(8k verbage
On or about September 16, 2011, Alpha Capital Anstalt, a Liechtenstein corporation with its principal place of business in Vaduz, Liechtenstein (“plaintiff”), filed an action against Advanced Cell Technology, Inc. (the “Company”) in the United States District Court for the Southern District of New York, Case No. 11 CIV 6458. Plaintiff alleges that it is or was a holder of various convertible notes and warrants issued by the Company, and that by reason of certain transactions between the Company and JMJ Financial, Inc. during 2010, the exercise and conversion prices in plaintiff’s convertible notes and warrants should have been reset. Plaintiff demands a preliminary and permanent injunction directing that the Company deliver to it at least 39,514,859 shares of its common stock, as well as monetary damages in an amount to be determined at trial. The Company intends to defend against this action vigorously.

Although not currently named as plaintiffs in this or other actions against the Company, in the event all other holders of convertible notes and warrants issued by the Company similarly situated to plaintiff were to file substantially similar actions based upon substantially similar claims and allegations, the Company estimates that the number of shares of common stock such holders of convertible notes could demand would be approximately 8 million, and the number of additional warrants convertible into shares of common stock such holders of warrants could demand would be approximately 380 million. The total number of shares of common stock of the Company currently outstanding is in excess of 1.62 billion.

alaeloa,

sure, that may apply elsewhere but it's not what is going on here. Do you really think that ACT Management would file an 8K today disclosing the following(see below) if any of your scenarios were true? ACT just settled with Midsummer Investments(66 million shares) for the same price resets the current Alpha lawsuit is for..Prior to that we settled with Gemini for about 21MM shares. Bristol won their lawsuit last year for 50MM shares. at .02 pps...Alpha won a prior suit in 2009 for 7.5MM shares. To my knowledge, no lawsuit has ever been "thrown out" for any reason. Hopefully our luck will change but to date ACT has not won a case so their track record is zero. Maybe this time around will be different but to not take them seriously is a huge mistake...

(todays 8k filing by ACT)
Item 8.01 Other Events

On or about September 16, 2011, Alpha Capital Anstalt, a Liechtenstein corporation with its principal place of business in Vaduz, Liechtenstein (“plaintiff”), filed an action against Advanced Cell Technology, Inc. (the “Company”) in the United States District Court for the Southern District of New York, Case No. 11 CIV 6458. Plaintiff alleges that it is or was a holder of various convertible notes and warrants issued by the Company, and that by reason of certain transactions between the Company and JMJ Financial, Inc. during 2010, the exercise and conversion prices in plaintiff’s convertible notes and warrants should have been reset. Plaintiff demands a preliminary and permanent injunction directing that the Company deliver to it at least 39,514,859 shares of its common stock, as well as monetary damages in an amount to be determined at trial. The Company intends to defend against this action vigorously.

Although not currently named as plaintiffs in this or other actions against the Company, in the event all other holders of convertible notes and warrants issued by the Company similarly situated to plaintiff were to file substantially similar actions based upon substantially similar claims and allegations, the Company estimates that the number of shares of common stock such holders of convertible notes could demand would be approximately 8 million, and the number of additional warrants convertible into shares of common stock such holders of warrants could demand would be approximately 380 million. The total number of shares of common stock of the Company currently outstanding is in excess of 1.62 billion.

I have an idea, why doesn't someone here spell out "what happen in the past" to make these lawsuits a joke or not to worry about? If someone here does that, I will post what lawsuits and settlements have cost you in the past year, say nothing about prior...deal?

how can these previously unsuccessful plaintiffs, where decisions against them have previously been rendered,

verbatim? give me a break. Where did you get that info? I have talked about the lawsuits for years and don't plan on revisting the whole scene. Do some homework..Cute enough?

none of what you stated is the least bit factual so how am I suppose to respond to that?

IMO, the 8K was written in such a way that you can rule out frivolous. No, it won't be the end of ACT, why would it? They will have to address the AS issue soon, we are at or over 1.7B shares fully diluted.

no worries according to this..:)

These new reemerging old law suites are just that...old! None of these plaintiffs will get anywhere. They've been tossed out before, they'll get tossed out again.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=67273136

ACT Receives Approval for First Human Embryonic Stem Cell Trial in Europe

Advanced Cell Tech (OTCBB:ACTC)
Today : Thursday 22 September 2011
Advanced Cell Technology, Inc. (“ACT”);(OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that it has received clearance from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to begin treating patients as part of a Phase 1/2 clinical trial for Stargardt’s Macular Dystrophy (SMD) using retinal pigment epithelium (RPE) derived from human embryonic stem cells (hESCs). ACT received similar approval from the Gene Therapy Advisory Committee (GTAC), which has responsibility for the ethical oversight of proposals to conduct clinical trials involving gene or stem cell therapies in the U.K. The European Medicines Agency (EMA) previously granted Orphan Drug designation for the company's RPE cell product for use in treating SMD.

“This is another important milestone for ACT and for the field of regenerative medicine,” said Gary Rabin, chairman and CEO of ACT. “We are pleased that the Moorfields Eye Hospital in London has agreed to participate as a site for this study as we continue to assess the capabilities of hESC-derived RPE cells to repair the retina and reduce the impact of these devastating eye diseases. We recently announced the dosing of the first patients in our Phase 1/2 clinical trials for Stargardt’s macular dystrophy and dry age-related macular degeneration (dry AMD) with hESC-derived RPE cells in the U.S., and both patients successfully underwent the outpatient transplantation surgeries. Clearance from the MHRA to begin an SMD trial in the U.K. is the first step in our European clinical trial program. Europe not only represents the world’s second-largest pharmaceutical market, but it is also home to some of the best eye hospitals and surgeons in the world. Building international relationships around our clinical programs, such as with Professor James Bainbridge at Moorfields Eye Hospital is very important to our strategy of developing new regenerative medicine therapies.”

Stargardt's Macular Dystrophy affects an estimated 80,000 to 100,000 patients in the U.S. and Europe, and causes progressive vision loss, usually starting in people between the ages of 10 to 20. Eventually, blindness results from photoreceptor loss associated with degeneration in the pigmented layer of the retina, the retinal pigment epithelium. The first patient to be treated in the U.S. with stem cell-derived RPE cells was a young woman who was already legally blind as a consequence of this disease. This newly-approved clinical trial in Europe will be a prospective, open-label study designed to determine the safety and tolerability of RPE cells derived from hESCs following sub-retinal transplantation to patients with advanced SMD, and it is similar in design to the FDA-cleared U.S. trial initiated in July.

“This is the first time an embryonic stem cell trial has ever been approved anywhere else in the world,” said Robert Lanza, M.D., ACT's chief scientific officer. “Stargardt’s disease is currently untreatable, and is one of the leading causes of juvenile blindness in the world. Collectively, degenerative eye diseases afflict over 25 million people in the U.S. and Europe alone. These diseases have a devastating impact on patients and their families, which has been a strong motivating factor for developing this new treatment. In Stargardt’s disease, the loss of RPE cells in the patient's macula causes a loss of photoreceptors – the cones and rods with which we see – leading to blindness. We believe that transplanting new, healthy RPE cells may provide an effective treatment for SMD and perhaps other macular degenerative diseases such as dry AMD. We are excited to start these trials in Europe, and look forward to analyzing the data we continue to collect in our ongoing trials to determine the engraftment and function of the transplanted RPE cells.”

The trial will be led by Professor James Bainbridge, consultant surgeon at Moorfields Eye Hospital, and Chair of Retinal Studies at University College London.

"Stargardt’s disease is a form of macular degeneration that causes disabling loss of sight in young people and is currently untreatable,” said Professor Bainbridge. “There is real potential that people with blinding disorders of the retina including Stargardt’s disease and age-related macular degeneration might benefit in the future from transplantation of retinal cells. The ability to generate retinal cells from stem cells in the laboratory has been a significant advance and the opportunity to help translate such technology into new treatments for patients is hugely exciting. Testing the safety of retinal cell transplantation in this clinical trial will be an important step towards achieving this aim.”

8K filed,

Item 8.01 Other Events

On or about September 16, 2011, Alpha Capital Anstalt, a Liechtenstein corporation with its principal place of business in Vaduz, Liechtenstein (“plaintiff”), filed an action against Advanced Cell Technology, Inc. (the “Company”) in the United States District Court for the Southern District of New York, Case No. 11 CIV 6458. Plaintiff alleges that it is or was a holder of various convertible notes and warrants issued by the Company, and that by reason of certain transactions between the Company and JMJ Financial, Inc. during 2010, the exercise and conversion prices in plaintiff’s convertible notes and warrants should have been reset. Plaintiff demands a preliminary and permanent injunction directing that the Company deliver to it at least 39,514,859 shares of its common stock, as well as monetary damages in an amount to be determined at trial. The Company intends to defend against this action vigorously.

Although not currently named as plaintiffs in this or other actions against the Company, in the event all other holders of convertible notes and warrants issued by the Company similarly situated to plaintiff were to file substantially similar actions based upon substantially similar claims and allegations, the Company estimates that the number of shares of common stock such holders of convertible notes could demand would be approximately 8 million, and the number of additional warrants convertible into shares of common stock such holders of warrants could demand would be approximately 380 million. The total number of shares of common stock of the Company currently outstanding is in excess of 1.62 billion.

sell? what's that got to do with you posting inaccurate info?..eom

ddls,


it is most important that you know what you're getting into. Do your due diligence first.

With due respect, maybe you should take your own advice? Whether it's the AS#, dilution or whatever, you have been off the mark. Now the lawsuits. Show us where any of the 3 lawsuits were "thrown out".
You may want to revisit this post as well..
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=67223601

louisa,

Here are the 3 active suits recently filed,
Gorton-Aronson cases demanding approx. $13MM
Alpha- undisclosed at this time

Alpha Capital Anstalt v. Advanced Cell Technology, Inc.
Filed: September 15, 2011 as 1:2011cv06458
Plaintiff: Alpha Capital Anstalt
Defendant: Advanced Cell Technology, Inc.
Type:Contract > Other Contract

Gorton v. Advanced Cell Technology, Inc. et al
Filed: August 25, 2011 as 1:2011cv11515
Plaintiff: John S Gorton
Defendants: Advanced Cell Technology, Inc. and Wilmington Trust, N.A.
Type:Other Statutes > Securities/Commodities

Aronson v. Advanced Cell Technology, Inc. et al
Filed: August 23, 2011 as 1:2011cv11492
Plaintiff: Gary D Aronson
Defendants: Advanced Cell Technology, Inc. and Wilmington Trust, N.A.
Type:Other Statutes > Securities/Commodities

Another NEW Lawsuit: Alpha Capital Anstalt

1:11-cv-06458-PAC Alpha Capital Anstalt v. Advanced Cell Technology, Inc.
Paul A. Crotty, presiding
Date filed: 09/15/2011
Date of last filing: 09/15/2011

Case Summary
Office: Foley Square Filed: 09/15/2011
Jury Demand: None Demand:
Nature of Suit: 190 Cause: 28:1332 Diversity-Breach of Contract
Jurisdiction: Diversity Disposition:
County: XX Out of U.S. Terminated:
Origin: 1 Reopened:

Lead Case: None
Related Case: None Other Court Case: None
Def Custody Status:
Flag: ECF

Plaintiff: Alpha Capital Anstalt represented by Kenneth A. Zitter Phone: (212) 532-8000
Fax: (212) 679-8998
Email: kzitter@aol.com

Defendant: Advanced Cell Technology, Inc.

gravel?..lol..that means what?

I was responding to the 2 statements you made below, neither of which is correct. So you now admit neither statement you made is correct and want to take the discussion somewhere else?..Is that the plan?


As for the AS issue, I think it's pretty safe to say it won't go above 1.7 billion- ish.

If Mr.Rabin's goal is to get off OTC he'd be making a mistake by diluting anymore than they already have

They are depending on the LOC with Socius for $17MM to get them through trials...How many shares for that?

What about the last settlement agreement with Midsummer that says we owe them 31MM shares when we "raise the AS#"????? In the meantime it cost us 3MM shares a month penalty until AS# is increased and we pay them what is owed.

And somehow you don't think the AS# will be increased or more dilution will happen?...ACT has already told you on both counts what will happen..

AS# will be increased no matter what...eom

spino,


ACT has about 70MM warrants that can be exercised at 10 cents.
This can be done at anytime until 2014. When warrants are exercised
ACT receives the money and then sellers can sell stock at anytime.
Also about 20MM options right now.

All of this can cause pressure on the stock if they exercise and sell but one never knows when this will happen. In the scheme of things, nothing to lose sleep over..

You need to go to last paragraph link in this post so you can see how things are set up..page 28
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=67141627

no, it means they were registered so they can be sold upon exercise if they choose to do so..

Thank poster twenty2 at ICELL for this,

http://investorstemcell.com/forum/act-main-forum-general-topics-science-press-releases-media/7110.htm

neither, just corrections and additions to the registration filings and prospectus from before..

Todays 424B3

Black Mountain Equities 4MM shares would be a new addition. They have never been listed as selling security holder prior.
(1) Represents shares of common stock issuable upon exercise of amended and restated warrants.
Not sure why or how they became part of the restated warrants..
Based in San Diego, California, Black Mountain Equities focuses on alternative investments including but not limited to PIPES, Distressed Debt, and Real Estate. For more information on Black Mountain Equities call (858) 382-1896.

T.R. Winston & Company, LLC

One of 2 things happened here. If you go to comparison table(below) you will see that todays number is exactly 7MM shares less than prior 424B3.
a) prior prospectus should have subtracted out exercised shares and didn't.
b) they recently exercised 7MM warrants and ACT wanted it updated.

Changes like today happened back in March also..
http://www.sec.gov/Archives/edgar/data/1140098/000101376211000516/form424b3.htm

T.R. Winston & Company, LLC 4,618,241 4,618,241 (1)
Black Mountain Equities, Inc. 4,000,000 4,000,000 (1)
Page 28: Comparison table from prior 424B3
http://www.sec.gov/Archives/edgar/data/1140098/000114420411050294/v233688_424b3.htm

September Corporate Presentation:
http://www.advancedcell.com/documents/0000/0347/act-corporate-presentation---rodman-&-renshaw-conference---september-2011---final.pdf